ScripTOKYO – Shionogi & Co. Ltd. loosened ties with its HIV portfolio, including late-stage compound dolutegravir, by granting ViiV Healthcare global rights to the integrase inhibitor portfolio in
Pink SheetTOKYO – Shionogi & Co. Ltd. loosened ties with its HIV portfolio, including late-stage compound dolutegravir, by granting ViiV Healthcare global rights to the integrase inhibitor portfolio in
ScripThe Japanese pharmaceutical company Shionogi & Co. Ltd. has for the first time established a direct business presence in Europe, by setting up its European headquarters in London. The H.Q. will be
Pink SheetThe Japanese pharmaceutical company Shionogi & Co. Ltd. has for the first time established a direct business presence in Europe, by setting up its European headquarters in London. The H.Q. will be